1984 Nobel Prize in Physiology or Medicine
Reason for Award
for theories concerning the specificity in development and control of the immune system and the discovery of the principle for production of monoclonal antibodies
Laureates
Denmark
Germany
Argentina, 
United Kingdom of Great Britain and Northern Ireland
Explanation
Inside our bodies there is a defense system called immunity that fights germs and viruses. Mr. Jerne wondered how this system can spot only the enemies. Mr. Köhler and Mr. Milstein then found a way to make special "monoclonal antibodies" that stick exactly to one kind of enemy. These antibodies act like magnifying glasses that find one matching shape. Today they help doctors discover illnesses quickly and are even used as medicines, saving people all over the world.
Related Keywords
clonal selection theory
A model proposing that lymphocytes carry pre-existing, diverse antibody receptors and that only the clone whose receptor binds the antigen is selected to proliferate. This allows the immune system to target specific foreign molecules while usually sparing self components. Molecular genetic evidence accumulated in the 1960s placed the theory at the core of immunology. It explains booster vaccination effects and mechanisms of autoimmune diseases. Today, next-generation sequencing tracks real-time B-cell repertoires, refining the theory further.
monoclonal antibody
An antibody produced by a single B-cell clone, binding only one antigenic determinant (epitope). Hybridoma technology enabled its mass production. Monoclonal antibodies serve as diagnostic reagents, rapid virus tests, and therapeutics for cancers and autoimmune diseases. Recent engineering of Fc regions and glycan structures permits fine control of mechanisms of action. Bispecific antibodies and antibody–drug conjugates (ADCs) are derivative formats now dominating drug pipelines.
hybridoma
An immortal antibody-producing cell line created by fusing a B-cell with a myeloma cell using PEG. Selection in HAT medium allows growth of clones that secrete the desired antibody. Because the cells are immortal, identical antibodies can be produced indefinitely at high yield. Since the 1980s hybridoma generation has been a standard laboratory procedure and remains a first-line technique for antibody production combined with animal immunization.
immune network theory
Proposed by Jerne, this concept suggests that antibodies recognize epitopes on other antibodies, forming self-regulating loops. Antibody–antibody interactions explain how the immune system avoids over-reaction and autoimmunity. It evolved into idiotype network research, influencing vaccine design and tumor immunology. The theory was pioneering in framing immune balance as network dynamics. Modern mathematical models and systems-immunology tools are revisiting and expanding the idea.
antibody therapeutics
A class of medicines based on monoclonal antibodies. They target specific cell-surface molecules or cytokines, offering high efficacy with comparatively fewer side effects. Beginning with rituximab’s 1997 approval, indications have expanded across cancer, inflammation, and infectious diseases. Humanized and fully human antibody technologies reduce immunogenicity. Top-selling global drugs today are dominated by antibody therapeutics.
B cell
A lymphocyte lineage that differentiates in bone marrow and produces antibodies. Upon antigen stimulation, it becomes a plasma cell secreting large quantities of antibody. V(D)J recombination and somatic mutation create a diverse antibody repertoire. B cells are central targets in monoclonal antibody technology and mRNA vaccine development. Dysregulated self-reactive B cells cause autoimmune diseases.
epitope
A specific three-dimensional structure or amino-acid sequence on an antigen recognized by an antibody or T-cell receptor. Multiple epitopes exist on one protein and define immune targets. Monoclonal antibodies bind a single epitope with high affinity, granting precision in diagnostics and therapy. Peptide epitopes drive subunit vaccine development. Epitope mapping is crucial for drug discovery and understanding immune evasion.
diagnostic ELISA
A test that captures antigens with monoclonal antibodies and converts binding into color or light via an enzymatic reaction. It quantifies infections, hormones, or drug levels. High sensitivity and specificity with rapid readout make ELISA a clinical standard. COVID-19 antibody test kits apply the same principle. Reagent quality largely depends on antibody specificity.
humanized antibody
An antibody in which only the antigen-binding CDRs from an animal antibody are retained while the framework is replaced with human sequences. This lowers immunogenicity while preserving affinity. Produced by genetic engineering, it is a major therapeutic antibody format. Combined with fully human antibodies and nanobodies, it broadens treatment options. After patent expiry, biosimilar development has become active.
Fc engineering
A technique that introduces amino-acid substitutions or glycan modifications into the antibody constant (Fc) region to optimize effector functions and serum half-life. It enables enhanced ADCC, tuned complement activation, and prolonged circulation via altered FcRn binding. It is a key method to improve efficacy and safety of biologic drugs. Advances in structural analysis and computational design are increasing in-silico prediction accuracy.